雅培公司（ABT.N）表示，计划将其营养业务分拆为一家独立上市的公司，这家医疗科技巨头正寻求专注于其诊断和医疗器械业务。
Abbott Laboratories (ABT.N) said it plans to separate its nutrition business into an independent, publicly traded company, as the medtech giant looks to focus on its diagnostics and medical device businesses.
首席执行官罗伯特·福特表示：“此次分拆将使两家公司都受益，让各自在其所在市场获得最大成功。”该公司表示，分拆预计将于2027年底前完成。
"This separation will benefit both companies, setting each one up for maximum success in its respective market," said CEO Robert Ford. The separation is expected to be completed by the end of 2027, the company said.
雅培目前预计2026年销售增长约6%，而此前预期为6.5%至7.5%之间。
Abbott now expects 2026 sales growth of about 6%, compared with its prior expectation of between 6.5% and 7.5%.
该公司公布的季度调整后每股利润为1.42美元——根据伦敦证券交易所集团（LSEG）汇编的数据，这与分析师的普遍预期一致。雅培股价在盘前交易中下跌约2%。
The company reported quarterly adjusted profit per share of $1.42 — in line with analysts' average estimate, according to data compiled by LSEG. Abbott shares fell about 2% in premarket trading.